Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | HPGD | P15428 | 3/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11545620 | 0.91 | KDM4E (0.66) | ALDH1A1KDM4ELMNAHPGDUSP2 | |
| SCHEMBL22260537 | 0.90 | LMNA (0.78) | ALDH1A1KDM4ELMNAHPGDUSP2 | |
| SCHEMBL11544114 | 0.90 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNAHPGDUSP2 | |
| SCHEMBL11544757 | 0.89 | ALDH1A1 (0.64) | ALDH1A1KDM4ELMNAHPGDUSP2 | |
| SCHEMBL11542238 | 0.89 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAHPGDUSP2 | |
| SCHEMBL14881297 | 0.89 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAHPGDUSP2 | |
| SCHEMBL16581077 | 0.89 | ALDH1A1 (0.83) | ALDH1A1KDM4ELMNAHPGDUSP2 | |
| Piretanide SCHEMBL49473 | 0.89 | KDM4E (1.00) | ALDH1A1KDM4ELMNAHPGDUSP2 | |
| Piretanide SCHEMBL30230376 | 0.89 | KDM4E (1.00) | ALDH1A1KDM4ELMNAHPGDUSP2 | |
| Piretanide SCHEMBL1741994 | 0.89 | KDM4E (1.00) | ALDH1A1KDM4ELMNAHPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006110187-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-04-27 | — | — | US | disclosed |
| US-4161531-A | Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-17 | — | — | US | disclosed |
| US-4118397-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4111953-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4093735-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-06 | — | — | US | disclosed |
| US-4010273-A | DIURETICS, SALURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | ALDH1A1 835/4885KDM4E 2426/4885LMNA 4006/4885 |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | SLC1A2, SLC18A2, GRIN2C | ALDH1A1 1109/4885KDM4E 1867/4885LMNA 3939/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | ALDH1A1 889/4885KDM4E 2228/4885LMNA 3992/4885 |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | ALDH1A1 835/4885KDM4E 2426/4885LMNA 4006/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | ALDH1A1 625/4885KDM4E 2764/4885LMNA 4297/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | ALDH1A1 845/4885KDM4E 3717/4885LMNA 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.